[1] Troelstra MA, Witjes JJ, van Dijk AM, et al. Assessment of imaging modalities against liver biopsy in nonalcoholic fatty liver disease: theAmsterdam NAFLDkash cohort. J Magn Reson Imaging, 2021, 54(6):1937-1949. [2] Andersen G, Plum-Mörschel L, Hockings PD, et al. Clinical characteristics of a non-alcoholic fatty liver disease population across the fibrosis spectrum measured by magnetic resonance elastography: analysis of screening data. Adv Ther, 2020, 37(12):4866-4876. [3] Ciardullo S, Oltolini A, Cannistraci R, et al. Sex-related association of nonalcoholic fatty liver disease and liver fibrosis with body fat distribution in the general US population. Am J Clin Nutr, 2022, 115(6):1528-1534. [4] 宁静,姚明解,刘树红,等.肝脏弹性测定对非酒精性脂肪性肝纤维化诊断价值的评估.中华肝脏病杂志,2020,28(7):567-572. [5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,2(21):30-39. [6] 中华医学会肝病学分会、消化病学分会及感染病学分会.肝纤维化诊断及治疗共识(2019年).实用肝脏病杂志,2019,22(6):793-803. [7] Alqahtani SA, Golabi P, Paik JM, et al. Performance of noninvasive liver fibrosis tests in morbidly obese patients with nonalcoholic fatty liver disease. Obes Surg, 2021, 31(5):2002-2010. [8] 周兴,易怀红,宋廉.超声弹性成像声触诊组织成像量化指标评估肝血吸虫病患者肝纤维化价值临床研究.实用肝脏病杂志,2022,25(3):399-402. [9] Ogino Y, Wakui N, Nagai H, et al. Comparison of strain elastography and shear wave elastography in diagnosis of fibrosis in nonalcoholic fatty liver disease. J Med Ultrason, 2023, 50(2):187-195. [10] Wu Y, Liu Q, Wang Y, et al. Diagnostic efficiency on ultrasound shear wave elastography in evaluation of steatosis severity for non-alcoholic fatty liver disease: a rat model. Eur J Med Res, 2023, 28(1):75-76. [11] 朱琳,陈洋,杨青,等.超声弹性成像评估自身免疫性肝炎患者肝纤维化分期价值分析.实用肝脏病杂志,2023,26(3):360-363. [12] Minamikawa T, Hase E, Ichimura-Shimizu M, et al.Assessment of ultra-early-stage liver fibrosis in human non-alcoholic fatty liver disease by second-harmonic generation microscopy.Int J Mol Sci, 2022, 23(6):3357. [13] Vieira Barbosa J, Milligan S, Frick A, et al.Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease.Am J Gastroenterol, 2022, 117(3):453-461. [14] 何舒丽,李双杰,刘敏,等.瞬时弹性成像技术,APRI及FIB-4对儿童非酒精性脂肪性肝病肝纤维化诊断价值的研究.中华肝脏病杂志,2022,30(1):81-86. [15] Hydes T, Brown E, Hamid A, et al.Current and emerging biomarkers and imaging modalities for nonalcoholic fatty liver disease: clinical and research applications.Clin Ther, 2021, 43(9):1505-1522. [16] Wang Q , Xie W , Liu L ,et al.Serum markers for predicting advanced fibrosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease.Medicine, 2021, 100(18):e25327. [17] Harrison SA, Gawrieh S, Roberts K, et al.Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol, 2021, 75(2):284-291. [18] Hudert CA, Tzschätzsch H, Rudolph B, et al.How histopathologic changes in pediatric nonalcoholic fatty liver disease influence in vivo liver stiffness.Acta Biomater, 2021, 123(3):178-186. [19] Park JH, Seo N, Chung YE, et al.Noninvasive evaluation of liver fibrosis: comparison of the stretched exponential diffusion-weighted model to other diffusion-weighted MRI models and transient elastography. Eur Radiol, 2021, 31(7):4813-4823. [20] Goldman O, Ben-Assuli O, Rogowski O, et al.Non-alcoholic fatty liver and liver fibrosis predictive analytics: risk prediction and machine learning techniques for improved preventive medicine.J Med Syst, 2021, 45(2):22. |